While the effects of such treatment on acute infection of CNS cells needs to be further explored, these therapeutic CD33 targeting antibodies have been used for Hepatitis B virus, AML treatment and Alzheimer Disease,39, 40, 41 moving them closer to be tested in a clinical setting in HIV infection and with more extensive CNS assessment than what was possible in the BCN02 trial. The gene discussed is CD33; the disease is acute myeloid leukemia.